Overview

First-line Therapy of Stage IV Colorectal Cancer

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

Assessment of safety and toxicity, definition of the dose limiting toxicity (DLT) of the combination therapy consisting of Capecitabine, Oxaliplatin, Bevacizumab and Imatinib.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Cologne

Collaborators:

Novartis
Roche Pharma AG
Sanofi

Treatments:

Bevacizumab
Capecitabine
Imatinib Mesylate
Oxaliplatin